An open label, randomized phase III trial comparing 2.5 year duration of letrozole (Femara) treatment with 5 year duration in patients previously treated for endocrine sensitive early breast cancer

Trial Profile

An open label, randomized phase III trial comparing 2.5 year duration of letrozole (Femara) treatment with 5 year duration in patients previously treated for endocrine sensitive early breast cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Letrozole (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms IDEAL
  • Most Recent Events

    • 23 Aug 2017 Results published online in the Journal of the National Cancer Institute (online publication date: 23 August 2017; print publication date: January 2018)
    • 06 Oct 2011 Additional source identified (Netherlands Trial Registry), and 3 identifiers, study sponsor (Novartis) and lead investigator added
    • 06 Oct 2011 Planned number of patients changed from 1100 to 1823, as reported in the Netherlands Trial Registry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top